Welcome to our dedicated page for Merit Medical Systems news (Ticker: MMSI), a resource for investors and traders seeking the latest updates and insights on Merit Medical Systems stock.
Merit Medical Systems Inc (NASDAQ: MMSI) is a leading manufacturer of medical devices used in diagnostic and interventional cardiology, radiology, and endoscopy procedures. Headquartered in South Jordan, Utah, the company employs approximately 7,000 individuals globally. Merit Medical's extensive product portfolio includes inflation devices for angioplasty and stent placement, diagnostic and therapeutic catheters, guide wires, thrombolytic catheters, fluid dispensing systems, angiography accessories, and custom angiography kits. The company's products are marketed across the United States, Europe, and around the world through direct sales forces and distributors.
Merit Medical operates primarily in two segments: Cardiovascular, which constitutes the majority of its revenue, and Endoscopy. The company is renowned for its innovative healthcare technology, with recent notable achievements including FDA 510(k) clearance for their SCOUT® MD™ Surgical Guidance System, designed to enhance the precision of tumor excision in breast cancer surgeries.
In 2024, Merit Medical commenced the MOTION study, a multicenter, prospective, randomized, controlled trial comparing genicular artery embolization (GAE) using Embosphere® Microspheres to corticosteroid injections for treating knee osteoarthritis. This study underscores the company's commitment to evidence-based medicine and patient-centric care. Additionally, the company recently launched the Micro ACE Advanced Micro-Access System and the Siege Vascular Plug, which are expected to significantly improve patient outcomes in vascular procedures.
Financially, the company has introduced a Continued Growth Initiatives Program with robust targets set for 2026. Merit Medical has consistently focused on innovation, investment in research, and strategic expansion, making it a pivotal player in the medical technology sector.
For the latest updates and detailed financial data, Merit Medical Systems regularly schedules earnings calls and provides comprehensive reports which can be accessed by interested stakeholders.
Merit Medical Systems (NASDAQ: MMSI) reported Q3 2021 revenue of $267.0 million, a 9.4% increase from Q3 2020. The company achieved a GAAP EPS of $0.21, recovering from a loss of ($0.05) per share last year. Non-GAAP EPS rose to $0.52 from $0.42. The growth was fueled by strong sales in the Cardiovascular segment, particularly in Peripheral and Cardiac Interventions. Merit's non-GAAP gross margin improved to 49.1%, aided by operational efficiencies despite inflationary pressures. The company reaffirmed its full-year revenue growth guidance at 9%-10%.
Merit Medical Systems, Inc. (NASDAQ: MMSI) announced financial results for the quarter ending September 30, 2021, to be released after market close on October 28, 2021. The company will conduct a conference call for investors at 5:00 p.m. Eastern on the same day. Merit is known for its proprietary disposable devices used in various medical fields including cardiology and oncology, employing around 6,700 individuals worldwide with facilities in several countries.
The WRAPSODY FIRST Study revealed promising results for the WRAPSODY Endoprosthesis by Merit Medical Systems (MMSI), showing a 100% target lesion primary patency (TLPP) rate at 30 days and an 84.6% TLPP rate at 12 months among 46 subjects treated for arteriovenous access circuit stenosis. The study indicated a 65.9% access circuit primary patency (ACPP) rate at one year, supporting the device's safety and effectiveness. The company plans a large WAVE Study to further validate these results and pursue FDA approval.
Merit Medical Systems has launched the One-Vac™ Evacuated Drainage Bottle, a device designed to aspirate, remove, or sample body fluids. This innovative product is particularly beneficial for thoracentesis and paracentesis procedures. Its advanced features include an ergonomic handle for easy flow regulation and a durable construction to minimize spills. The launch, praised by early users, supports Merit's expanding drainage portfolio, reflecting the company's commitment to incorporating physician feedback and advancing technologies.
Merit Medical Systems, Inc. (NASDAQ: MMSI) reported Q2 2021 revenue of $280.3 million, a 28.4% increase from Q2 2020. GAAP net income was $4.9 million ($0.09/share), contrasting with a loss of ($19.1 million) last year. Non-GAAP net income reached $35.3 million ($0.62/share), up 103%. The company updated its full-year guidance, projecting net sales between $1,060 - $1,070 million, reflecting a growth of 9% - 10% year-over-year. Cash on hand increased to $70 million, while long-term debt decreased to $293 million.
Merit Medical Systems, Inc. (NASDAQ: MMSI) announced it will release its financial results for Q2 2021 on July 29, 2021, after market close. An investor conference call will follow at 5:00 p.m. Eastern time on the same day. The call can be accessed domestically at (844) 578-9672 and internationally at (508) 637-5656, with a live webcast available on merit.com. Founded in 1987, Merit manufactures disposable medical devices for interventional procedures and serves clients worldwide, employing about 6,500 people across multiple global locations.
Merit Medical Systems (NASDAQ: MMSI) reported Q1 2021 revenue of $248.9 million, up 2.2% from Q1 2020. The GAAP EPS stood at $0.19, a turnaround from a loss of ($0.06) in the previous year. Non-GAAP EPS increased to $0.52 from $0.38. The company's GAAP gross margin was 45.0%, up from 42.6% year-over-year. A strong cash flow of $29 million was generated. For FY 2021, Merit forecasts net revenue between $994 million and $1,014 million, anticipating modest growth in the cardiovascular and endoscopy segments.
Merit Medical Systems, Inc. (NASDAQ: MMSI) will announce its Q1 financial results for the period ending March 31, 2021, on April 29, 2021, after market close. The company will host a conference call at 5:00 p.m. Eastern Time on the same day, with details available on their website. Founded in 1987, Merit specializes in disposable medical devices for interventional procedures across various fields, including cardiology and oncology, serving a global client base.
SOUTH JORDAN, Utah, April 08, 2021 (GLOBE NEWSWIRE) -- Merit Medical Systems (NASDAQ: MMSI), a leader in disposable medical devices for interventional, diagnostic, and therapeutic procedures, will participate in the 20th Annual Needham Healthcare Conference. The event is set for April 15 at 2:15 p.m. ET, featuring a fireside chat with CEO Fred Lampropoulos and CFO Raul Parra. Merit Medical, headquartered in Utah, operates globally with a workforce of about 6,000, catering to hospitals and healthcare facilities across various regions.
Merit Medical Systems (NASDAQ: MMSI) has initiated its pivotal WAVE Study to assess the safety and effectiveness of the WRAPSODY Endovascular Stent Graft for treating dialysis outflow circuit stenosis or occlusion. The first two patients have been enrolled at RAC Surgery Center, Raleigh, NC. This multicenter study aims to recruit 357 patients across the U.S., Europe, Canada, and New Zealand, with a two-year follow-up. The WRAPSODY system, already holding a CE Mark, is designed to improve vascular access in over two million global hemodialysis patients, addressing common complications in dialysis procedures.
FAQ
What is the current stock price of Merit Medical Systems (MMSI)?
What is the market cap of Merit Medical Systems (MMSI)?
What does Merit Medical Systems Inc specialize in?
Where is Merit Medical Systems headquartered?
What are the main product segments of Merit Medical Systems?
What recent study has Merit Medical initiated?
What is the SCOUT® MD™ Surgical Guidance System?
How does Merit Medical distribute its products?
What is the significance of the Micro ACE Advanced Micro-Access System?
What is the Siege Vascular Plug used for?
What is Merit Medical's employment size?
What are some of the financial initiatives of Merit Medical?
